Bullish Case: Known: HCKT’s return-surface likelihood concentrates near small sub-year returns (~-5% to +10%) and recent tape is mean-reverting (about flat vs last week). Inferred: backwardation implies longer-dated upside pricing is less penalized. Prior “sideways ±10%” calls (~40–48%) matched the lack of follow-through lower; >+25% hasn’t shown, so this tilts to a modest grind toward ~$11–$13 rather than a surge.

Bearish Case: Known: the same return surface also has meaningful likelihood mass in deeper negatives, while HCKT is still far below prior levels (-56% YoY). Options show very high near-term put IV (e.g., 2.5P/5P), and SPY’s vol surface reflects persistent downside IV skew. Inferred: hedge-cost pressure can keep a ceiling under rebounds. Since price hasn’t broken down recently, bearish odds shift slightly lower vs prior <$10 (~20–25%) calls. Oracle (non-prescriptive): watch the Aug21 close vs $10; if it fails and IV stays elevated/backwardated, downside skew likely dominates.

Potential Outcomes:

1. 50% Range: Aug21 close $9.4–$10.9 (return-surface density + mean reversion).
2. 27% Drift-down: Aug21 < $10; Sep18 < $9.3 (put-skew + SPY downside IV).
3. 13% Recovery: $11.5–$13 by Sep18 if contract/upgrade news lifts calls (falsifiable: call bid uptick).
4. 7% Whipsaw: IV repricing around Sep FOMC/earnings (direction unclear).
5. 2% Tail negative: $8–$9 on litigation/major miss.
6. 1% Tail positive: >$14 on M&A/large award.

July 28, 2026